1365170-20-2 Usage
Uses
Used in Pharmaceutical Industry:
1-(Bicyclo[3,1,0]hexan-3-yl)-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine is used as a potential pharmaceutical agent for its possible biological and pharmacological properties. 1-(Bicyclo[3,1,0]hexan-3-yl)-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine's unique structure and chemical properties may contribute to the development of new drugs with specific therapeutic applications.
Used in Chemical Research:
1-(Bicyclo[3,1,0]hexan-3-yl)-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine serves as a subject of interest in chemical research due to its complex structure and the potential for novel chemical reactions and interactions. Studying 1-(Bicyclo[3,1,0]hexan-3-yl)-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine can lead to a better understanding of its reactivity and the development of new synthetic pathways.
Used in Material Science:
1-(Bicyclo[3,1,0]hexan-3-yl)-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine's steric and electronic properties make it a candidate for material science applications, where its unique characteristics could be leveraged to create new materials with specific properties for various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1365170-20-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,5,1,7 and 0 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1365170-20:
(9*1)+(8*3)+(7*6)+(6*5)+(5*1)+(4*7)+(3*0)+(2*2)+(1*0)=142
142 % 10 = 2
So 1365170-20-2 is a valid CAS Registry Number.
1365170-20-2Relevant academic research and scientific papers
Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H- pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1
Le Brazidec, Jean-Yves,Pasis, Angela,Tam, Betty,Boykin, Christina,Black, Cheryl,Wang, Deping,Claassen, Gisela,Chong, Jer-Hong,Chao, Jianhua,Fan, Junhua,Nguyen, Khanh,Silvian, Laura,Ling, Leona,Zhang, Lin,Choi, Michael,Teng, Min,Pathan, Nuzhat,Zhao, Shuo,Li, Tony,Taveras, Art
, p. 2070 - 2074 (2012/04/23)
Since the early 2000s, the Aurora kinases have become major targets of oncology drug discovery particularly Aurora-A and Aurora-B kinases (AKA/AKB) for which the selective inhibition in cells lead to different phenotypes. In addition to targeting these Aurora kinases involved in mitosis, CDK1 has been added as a primary inhibition target in hopes of enhancing the cytotoxicity of our chemotypes harboring the pyrazolopyrimidine core. SAR optimization of this series using the AKA, AKB and CDK1 biochemical assays led to the discovery of the compound 7h which combines strong potency against the 3 kinases with an acceptable microsomal stability. Finally, switching from a primary amide to a two-substituted pyrrolidine amide gave rise to compound 15a which exhibited the desired AKA/CDK1 inhibition phenotype in cells but showed moderate activity in animal models using HCT116 tumor cell lines.
